Payers Should Brace For Next Hepatitis C Drug “Onslaught” – Express Scripts
This article was originally published in The Pink Sheet Daily
Express Scripts anticipates that the launch of new treatments in 2014 will replicate some of the dynamics in the hepatitis C market in 2011.
You may also be interested in...
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.
Outcomes and disease progression could be clear cut, lending the rare disease treatment to innovative contracting. But the amount of money at stake is likely to complicate things.